Скачать или смотреть Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT

Martine Piccart, MD, PhD, from the Free University of Brussels, Brussels, Belgium, describes the MINDACT trial in patients with early breast cancer (NCT00433589), which she presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. This trial determined whether having results from the MammaPrint test, which determines the genomic signature of each patient, alters the way in which women with early breast cancer are treated. Prof. Piccart discusses the results of the study, indicating that patients with high clinical risk but a low risk MammaPrint signature who did not receive adjuvant therapy, had excellent outcomes when determining distant metastasis-free survival (DMFS) at 5 years. She suggests that within this group, after consultation with the patients, the option of not having adjuvant chemotherapy may be explored. She also points out that in patients with low clinical risk, the MammaPrint test is not required as this group already has an excellent prognosis.